Kura Oncology Stock Alpha and Beta Analysis
| KURA Stock | USD 10.39 0.17 1.66% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Kura Oncology. It also helps investors analyze the systematic and unsystematic risks associated with investing in Kura Oncology over a specified time horizon. Remember, high Kura Oncology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Kura Oncology's market risk premium analysis include:
Beta 1.87 | Alpha 0.15 | Risk 4.27 | Sharpe Ratio 0.0515 | Expected Return 0.22 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Kura Oncology Backtesting, Kura Oncology Valuation, Kura Oncology Correlation, Kura Oncology Hype Analysis, Kura Oncology Volatility, Kura Oncology History and analyze Kura Oncology Performance. Kura Oncology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Kura Oncology market risk premium is the additional return an investor will receive from holding Kura Oncology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Kura Oncology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Kura Oncology's performance over market.| α | 0.15 | β | 1.87 |
Kura Oncology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Kura Oncology's Buy-and-hold return. Our buy-and-hold chart shows how Kura Oncology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Kura Oncology Market Price Analysis
Market price analysis indicators help investors to evaluate how Kura Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Kura Oncology shares will generate the highest return on investment. By understating and applying Kura Oncology stock market price indicators, traders can identify Kura Oncology position entry and exit signals to maximize returns.
Kura Oncology Return and Market Media
The median price of Kura Oncology for the period between Fri, Oct 3, 2025 and Thu, Jan 1, 2026 is 10.32 with a coefficient of variation of 7.88. The daily time series for the period is distributed with a sample standard deviation of 0.82, arithmetic mean of 10.42, and mean deviation of 0.66. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Insider Trading | 10/10/2025 |
2 | HC Wainwright Co. Reiterates Kura Oncology Buy Recommendation - Nasdaq | 10/20/2025 |
3 | Kura Oncology reports Q3 EPS , consensus KURA | 11/04/2025 |
4 | Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI , the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mut... | 11/13/2025 |
5 | KOMZIFTI Added to National Comprehensive Cancer Network Guidelines for Acute Myeloid Leukemia | 11/25/2025 |
6 | First U.S. Commercial Sale of KOMZIFTI Triggers 135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin | 12/02/2025 |
7 | Kura Oncology Is Down 7.2 percent After First KOMZIFTI Sale Triggers 135M Milestone Payment | 12/03/2025 |
8 | Walleye Capital LLC Reduces Holdings in Kura Oncology, Inc. KURA | 12/08/2025 |
9 | Kura Oncology Trading Down 4.6 percent Heres Why | 12/09/2025 |
10 | Kura Oncology Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval | 12/16/2025 |
11 | Disposition of 35000 shares by Francis Burrows of Kura Oncology at 4.8 subject to Rule 16b-3 | 12/18/2025 |
12 | Kura Oncology shows market leadership with jump to 93 RS rating - MSN | 12/23/2025 |
About Kura Oncology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Kura or other stocks. Alpha measures the amount that position in Kura Oncology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Kura Oncology Upcoming Company Events
As portrayed in its financial statements, the presentation of Kura Oncology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kura Oncology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Kura Oncology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Kura Oncology. Please utilize our Beneish M Score to check the likelihood of Kura Oncology's management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Kura Oncology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Kura Oncology Backtesting, Kura Oncology Valuation, Kura Oncology Correlation, Kura Oncology Hype Analysis, Kura Oncology Volatility, Kura Oncology History and analyze Kura Oncology Performance. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Kura Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.